Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovati ...
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results